(3,5-dimethoxyphenyl)methanesulfonyl chloride | 1194375-54-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3,5-dimethoxyphenyl)methanesulfonyl chloride
• 英文别名: (3,5-Dimethoxyphenyl)methanesulfonyl chloride
• CAS: 1194375-54-6
• 化学式: C₉H₁₁ClO₄S
• 分子量: 250.703
• InChiKey: ACZRENUAHPAJGI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  61
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3,5-dimethoxyphenyl)methanesulfonyl chloride 在 ferrous(II) sulfate heptahydrate 、 三乙胺 、 三氟乙酸 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 18.0h， 生成 (2-amino-3,5-dimethoxyphenyl)methanesulfonic acid
  参考文献：
  名称：

  O-(芳磺酰基)羟胺的氨基重排：轻松获得邻磺酰基苯胺

  摘要：

  据报道，羟胺衍生物的芳族重排可从简单的起始原料直接生成邻磺酰基苯胺。这是通过形成新的 CN 键来实现的，该键对邻位异构体具有出色的区域控制水平，这被认为是在 CN 键形成步骤中发生有吸引力的非共价相互作用的结果。

  DOI：

  10.1002/anie.202204025
• 作为产物：
  描述：

  3,5-二甲氧基溴苄 在 sodium sulfite 、 三氯氧磷 作用下， 以 水 、 丙酮 、 乙腈 为溶剂， 反应 4.0h， 生成 (3,5-dimethoxyphenyl)methanesulfonyl chloride
  参考文献：
  名称：

  O-(芳磺酰基)羟胺的氨基重排：轻松获得邻磺酰基苯胺

  摘要：

  据报道，羟胺衍生物的芳族重排可从简单的起始原料直接生成邻磺酰基苯胺。这是通过形成新的 CN 键来实现的，该键对邻位异构体具有出色的区域控制水平，这被认为是在 CN 键形成步骤中发生有吸引力的非共价相互作用的结果。

  DOI：

  10.1002/anie.202204025

文献信息

• ASYMMETRIC CATALYST AND PROCESS FOR PREPARING OPTICALLY ACTIVE ALCOHOLS USING THE SAME
  申请人：Watanabe Masahito

  公开号：US20100261924A1

  公开（公告）日：2010-10-14

  The present invention provides an organic metal compound, a ligand, an asymmetric catalyst, and a process for preparing optically-active alcohols using the asymmetric catalyst. The organic metal compound of the present invention is expressed by the following general formula (1): wherein in general formula (1), R 1 and R 2 are a mutually identical or mutually different, unsubstituted or substituted alkyl group, aryl group, cycloalkyl group, or R 1 and R 2 are bound to form an alicyclic ring, R 3 is a hydrogen atom or an alkyl group, R 4 is a branched alkyl group or an alkyl group that does or does not form a ring by itself, or an unsubstituted or substituted aryl group, or an unsubstituted or substituted heterocyclic group, Ar is an unsubstituted or substituted cyclopentadienyl group that is bound to M via a π bond, or an unsubstituted or substituted benzene, X is a hydride group or an anionic group, M is ruthenium, rhodium or iridium, L is a solvent molecule or a water molecule, l is 1 or 2, m is an integer from 0 to 2, n is 0 or 1, and when n is 0, X does not exist, and * represents asymmetric carbon, wherein R 4 is not a camphor group, a camphor derivative group, an isopropyl group or a phenyl group whenever R 1 and R 2 are both a phenyl group.

  本发明提供一种有机金属化合物、配体、不对称催化剂以及利用该不对称催化剂制备光学活性醇的方法。本发明的有机金属化合物由以下通用式（1）表示： 在通用式（1）中，R1和R2是相互相同或相互不同的未取代或取代的烷基基团、芳基团、环烷基团，或R1和R2结合形成脂环，R3是氢原子或烷基基团，R4是支链烷基基团或自身形成环或不形成环的烷基基团，或未取代或取代的芳基团，或未取代或取代的杂环基团，Ar是通过π键与M结合的未取代或取代的环戊二烯基团，或未取代或取代的苯，X是氢化物基团或阴离子基团，M是钌、铑或铱，L是溶剂分子或水分子，l为1或2，m为0到2的整数，n为0或1，当n为0时，X不存在，*代表不对称碳，其中当R1和R2均为苯基团时，R4不是藿香基团、藿香衍生基团、异丙基团或苯基团。
• [EN] N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS<br/>[FR] DÉRIVÉS DE N-(HÉTÉROARYL)-SULFONAMIDE UTILES COMME INHIBITEURS DE S100
  申请人：ACTIVE BIOTECH AB

  公开号：WO2014184234A1

  公开（公告）日：2014-11-20

  A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.

  化合物的化学式（I），或其药学上可接受的盐以及包含该化合物的药物组合物。该化合物是S100A9与相互作用伙伴（如RAGE、TLR4和EMMPRIN）之间相互作用的抑制剂，因此在治疗癌症、自身免疫性疾病、炎症性疾病和神经退行性疾病等疾病方面具有用处。
• N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS
  申请人：Active Biotech AB

  公开号：US20160115158A1

  公开（公告）日：2016-04-28

  A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.

  化合物(I)的配方，或其药学上可接受的盐和包含该化合物的药物组合物。该化合物是S100A9与相互作用伙伴如RAGE、TLR4和EMMPRIN之间相互作用的抑制剂，因此在治疗癌症、自身免疫性疾病、炎症性疾病和神经退行性疾病等疾病中有用。
• Asymmetric catalyst and process for preparing optically active alcohols using the same
  申请人：Kanto Kagaku Kabushiki Kaisha

  公开号：EP2239057A1

  公开（公告）日：2010-10-13

  The present invention provides an organic metal compound, a ligand, an asymmetric catalyst, and a process for preparing optically-active alcohols using the asymmetric catalyst. The organic metal compound of the present invention is expressed by the following general formula (1): wherein in general formula (1), R1 and R2 are a mutually identical or mutually different, unsubstituted or substituted alkyl group, aryl group, cycloalkyl group, or R1 and R2 are bound to form an alicyclic ring, R3 is a hydrogen atom or an alkyl group, R4 is a branched alkyl group or an alkyl group that does or does not form a ring by itself, or an unsubstituted or substituted aryl group, or an unsubstituted or substituted heterocyclic group, Ar is an unsubstituted or substituted cyclopentadienyl group that is bound to M via a π bond, or an unsubstituted or substituted benzene, X is a hydride group or an anionic group, M is ruthenium, rhodium or iridium, L is a solvent molecule or a water molecule, 1 is 1 or 2, m is an integer from 0 to 2, n is 0 or 1, and when n is 0, X does not exist, and * represents asymmetric carbon, wherein R4 is not a camphor group, a camphor derivative group, an isopropyl group or a phenyl group whenever R1 and R2 are both a phenyl group.

  本发明提供了一种有机金属化合物、一种配体、一种不对称催化剂以及一种使用该不对称催化剂制备光学活性醇的工艺。本发明的有机金属化合物由以下通式（1）表示： 其中通式（1）中，R1 和 R2 是相互相同或相互不同的未取代或取代的烷基、芳基、环烷基，或 R1 和 R2 结合形成脂环，R3 是氢原子或烷基，R4 是支链烷基或本身形成或不形成环的烷基，或未取代或取代的芳基，或未取代或取代的杂环基、Ar 是通过 π 键与 M 结合的未取代或取代的环戊二烯基，或未取代或取代的苯， X 是氢化物基团或阴离子基团，M 是钌、铑或铱，L 是溶剂分子或水分子、1 是 1 或 2，m 是 0 至 2 的整数，n 是 0 或 1，当 n 为 0 时，X 不存在，* 代表不对称碳，其中当 R1 和 R2 都是苯基时，R4 不是樟脑基团、樟脑衍生物基团、异丙基团或苯基。
• N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors
  申请人：Active Biotech AB

  公开号：US10125125B2

  公开（公告）日：2018-11-13

  A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between SI 00A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.

  一种式 (I) 的化合物或其药学上可接受的盐以及包含该化合物的药物组合物。该化合物是 SI 00A9 与 RAGE、TLR4 和 EMMPRIN 等相互作用伙伴之间相互作用的抑制剂，因此可用于治疗癌症、自身免疫性疾病、炎症性疾病和神经退行性疾病等疾病。